Is Biocartis Group NV (BCART) stock worth anything in 2026?

No. On 31 October 2023 secured creditors seized Biocartis Group NV's operating subsidiaries and shareholders were told shares are expected to be worth zero with no distribution. As of 24 July 2026 BCART still trades on Euronext Brussels with a market cap around EUR 27.2 million but is in active liquidation.

Who owns Biocartis now?

The real operating business, Biocartis NV and Biocartis US Inc, is owned by a new private holding company controlled by former secured bondholders since the 31 October 2023 creditor enforcement. The listed shell Biocartis Group NV (BCART) retains only nominal residual assets and is being wound down.

Is Biocartis profitable in 2026?

Unclear. The 2023 recapitalization injected EUR 40 million equity and cut about EUR 132 million of debt specifically to fund the operating business to EBITDA breakeven by end-2024, but no audited post-2023 financials for the now-private business have been published to confirm that target was hit.

Could AI replace Biocartis's Idylla platform?

Not immediately. Idylla's cartridge hardware and CE-IVD/US regulatory clearances resist pure software displacement and it has 2,500+ instrument placements in 95+ countries as of 7 July 2026. But AI-driven interpretation from Roche and Thermo Fisher is eroding Idylla's speed/simplicity edge, and no public evidence shows Biocartis shipping AI features itself.

What is Biocartis's biggest competitor?

QIAGEN's QIAstat-Dx is the most direct automation-platform rival to Idylla. Larger incumbents Roche (about 20% global IVD share) and Thermo Fisher, which submitted its Oncomine Dx Express multi-CDx in August 2025, also compete in oncology molecular diagnostics.

Did Biocartis get FDA approval for the Idylla CDx MSI test?

As of a 15 September 2025 report, FDA approval of the Idylla CDx MSI (microsatellite instability) test remained unconfirmed, meaning Biocartis still lacks confirmed US market access for this companion diagnostic as of that date.

Biotech tools companies · subsidiary of New Biocartis (privately held holding company owned by former secured creditors) · Belgium

Biocartis Group NV

biocartis.com ↗

Biocartis makes Idylla, a cartridge-based rapid molecular diagnostics platform for oncology testing.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from pending, 2026 · Every call on the record Checkpoint: FDA decision on Idylla CDx MSI test for US market access

The call

The listed shell Biocartis Group NV is being dissolved after a 2023 creditor takeover, while the operating Idylla business survives on installed placements but has not published audited results since the restructuring.

Biocartis makes Idylla, a machine that runs fast genetic tests for cancer, and has sold over 2,500 of them to hospitals and labs. The company itself is being shut down after a debt crisis in late 2023, so shareholders will lose money, but the machine business was bought by new owners and is still running. The problem is that much larger competitors like Roche, Thermo Fisher, and QIAGEN are all pushing machines that do the same job and are adding artificial intelligence to help doctors read the results faster and better, while there is no sign that Biocartis is keeping up with AI features. The one thing that matters now is whether the new Biocartis owners can prove the machine is still profitable and whether they can launch AI tools of their own before the big rivals lock up all the hospitals.

Why

AI pressure: Roche and Thermo Fisher AI-assisted NGS interpretation tools. AI-driven interpretation layers in rival NGS platforms could erode Idylla's fast-and-simple edge in oncology panels. Could AI do the core job? Only partly.

Bigger players: Roche cobas, QIAGEN QIAstat-Dx, Thermo Fisher Oncomine, Abbott/Exact Sciences. Roche holds about 20 percent of global IVD and QIAstat-Dx competes directly in Biocartis's automated-panel niche today. Could a giant copy it? Yes, easily.

What protects it. Over 2,500 Idylla systems placed in 95+ countries create switching costs that keep hospitals running existing cartridges.

What would change this call

FDA decision on Idylla CDx MSI test. Would show whether Biocartis can gain US market access against Roche/Thermo Fisher CDx rivals.
Publication of audited post-2023 operating company financials. Would confirm whether the operating business hit end-2024 EBITDA breakeven as promised.
Biocartis Group NV (BCART) formal dissolution or delisting. Would confirm the listed shell's expected wind-down and worthless equity.

Key numbers

2,500+ Idylla placements in 95+ countries (2026-07-07)
EUR 16M convertible bonds written to zero (2023-09-26)
H1 2023 product revenue EUR 23.5M, up from EUR 21.3M (2023-09-26)

Named risks

Listed shell Biocartis Group NV (BCART) in active liquidation, shares expected worthless. Severity: high
No audited post-2023 financials published for the now-private operating business. Severity: medium
FDA approval for Idylla CDx MSI companion diagnostic remains unconfirmed as of September 2025. Severity: medium
Wondfo-Cartis joint venture faces ten distributor lawsuits filed since Q1 2024, JV valued at EUR 0. Severity: medium
No public evidence of Biocartis deploying AI features while Roche and Thermo Fisher advance AI-driven CDx. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Roche	gaining on	Roche holds ~20% global IVD share and pushes AI-driven CDx expansion as of 10 June 2026
QIAGEN	contesting	QIAstat-Dx is cited as a direct automation-platform rival to Idylla, per 15 September 2025 report
Thermo Fisher	gaining on	Submitted Oncomine Dx Express multi-CDx for review in August 2025
Abbott	gaining on	Acquired Exact Sciences in March 2026, expanding oncology diagnostics footprint

Questions people ask

Is Biocartis Group NV (BCART) stock worth anything in 2026?: No. On 31 October 2023 secured creditors seized Biocartis Group NV's operating subsidiaries and shareholders were told shares are expected to be worth zero with no distribution. As of 24 July 2026 BCART still trades on Euronext Brussels with a market cap around EUR 27.2 million but is in active liquidation.
Who owns Biocartis now?: The real operating business, Biocartis NV and Biocartis US Inc, is owned by a new private holding company controlled by former secured bondholders since the 31 October 2023 creditor enforcement. The listed shell Biocartis Group NV (BCART) retains only nominal residual assets and is being wound down.
Is Biocartis profitable in 2026?: Unclear. The 2023 recapitalization injected EUR 40 million equity and cut about EUR 132 million of debt specifically to fund the operating business to EBITDA breakeven by end-2024, but no audited post-2023 financials for the now-private business have been published to confirm that target was hit.
Could AI replace Biocartis's Idylla platform?: Not immediately. Idylla's cartridge hardware and CE-IVD/US regulatory clearances resist pure software displacement and it has 2,500+ instrument placements in 95+ countries as of 7 July 2026. But AI-driven interpretation from Roche and Thermo Fisher is eroding Idylla's speed/simplicity edge, and no public evidence shows Biocartis shipping AI features itself.
What is Biocartis's biggest competitor?: QIAGEN's QIAstat-Dx is the most direct automation-platform rival to Idylla. Larger incumbents Roche (about 20% global IVD share) and Thermo Fisher, which submitted its Oncomine Dx Express multi-CDx in August 2025, also compete in oncology molecular diagnostics.
Did Biocartis get FDA approval for the Idylla CDx MSI test?: As of a 15 September 2025 report, FDA approval of the Idylla CDx MSI (microsatellite instability) test remained unconfirmed, meaning Biocartis still lacks confirmed US market access for this companion diagnostic as of that date.

Timeline

2026-07-07Biocartis and Discovery Life Sciences announce strategic biomarker services collaboration
2026-06-09Biocartis agreement with City of Hope on blood-based pancreatic cancer detection test
2026-01-12Biocartis announces Mayo Clinic collaboration on breast cancer gene-signature test
2025-09-15Report notes FDA approval of Idylla CDx MSI test still unconfirmed
2025-08-25Biocartis Group NV shareholders meeting formalizes liquidation governance
2025-07-25Special board report values Wondfo-Cartis stake at EUR 0, notes VAT dispute
2025-03-17Biocartis presents multiple Idylla research abstracts at USCAP 2025
2024-01Ten Wondfo-Cartis joint-venture distributors begin filing lawsuits
2023-10-31Secured creditors seize Biocartis operating subsidiaries, shell shares deemed worthless
2023-09-26Recapitalization agreement writes EUR 16M bonds to zero, injects EUR 40M equity

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation